SCHEMBL669522

SCHEMBL669522

CCOc1ccc(OCC)c(NC(=O)c2ccccc2)c1.[N-]=[N+]=[Zn](Cl)(Cl)(Cl)Cl

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.64
HDAC1 Q13547 3/20 0.60
HDAC8 Q9BY41 3/20 0.60
HDAC6 Q9UBN7 3/20 0.60
MAPT P10636 7/20 0.56
GAA P10253 2/20 0.56
TSHR P16473 3/20 0.55
MAPK1 P28482 1/20 0.55
POLB P06746 1/20 0.53
PLAU P00749 1/20 0.53
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 2/20 0.52
CREBBP Q92793 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HTT P42858 1/20 0.50
LMNA P02545 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1756430 0.89 EPHX1 (0.77) EPHX1HDAC1HDAC8HDAC6MAPT
SCHEMBL30434017 0.89 EPHX1 (0.77) EPHX1HDAC1HDAC8HDAC6MAPT
Ammonia Solution, Strong SCHEMBL28098407 0.88 EPHX1 (0.80) EPHX1HDAC1HDAC8HDAC6MAPT
Nitrogen SCHEMBL4600490 0.87 EPHX1 (0.74) EPHX1HDAC1HDAC8HDAC6MAPT
Nitrogen SCHEMBL1785874 0.86 EPHX1 (0.72) EPHX1HDAC1HDAC8HDAC6MAPT
Nitrogen SCHEMBL8004821 0.82 EPHX1 (0.67) EPHX1HDAC1HDAC8HDAC6MAPT
SCHEMBL5947431 0.80 MAPT (0.67) EPHX1HDAC1HDAC8HDAC6MAPT
SCHEMBL11328524 0.77 HDAC1 (0.72) EPHX1HDAC1HDAC8HDAC6MAPT
Nitrogen SCHEMBL4600884 0.76 MAPT (0.77) EPHX1HDAC1HDAC8HDAC6MAPT
Nitrogen SCHEMBL10785749 0.75 EPHX1 (0.58) EPHX1HDAC1HDAC8HDAC6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9127028-B2 Substrates for chromogenic detection and methods of use in detection assays and kits VENTANA MEDICAL SYSTEMS, INC. (US) 2015-09-08 US claimed
EP-2606055-B1 SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF USE IN DETECTION ASSAYS AND KITS VENTANA MED SYST INC (US) 2015-06-03 EP claimed
EP-2606055-A1 SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF USE IN DETECTION ASSAYS AND KITS Ventana Medical Systems, Inc. (US) 2013-06-26 EP claimed
US-20130115593-A1 SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF USE IN DETECTION ASSAYS AND KITS VENTANA MEDICAL SYSTEMS, INC. (US) 2013-05-09 US claimed
EP-2561095-A1 TWO-COLOR CHROMOGENIC IN SITU HYBRIDIZATION Ventana Medical Systems, Inc. (US) 2013-02-27 EP claimed
US-20130034853-A1 TWO-COLOR CHROMOGENIC IN SITU HYBRIDIZATION VENTANA MEDICAL SYSTEMS, INC. 2013-02-07 US claimed
WO-2012024185-A1 SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF USE IN DETECTION ASSAYS AND KITS VENTANA MEDICAL SYSTEMS, INC. (US) 2012-02-23 WO claimed
WO-2011133625-A1 TWO-COLOR CHROMOGENIC IN SITU HYBRIDIZATION VENTANA MEDICAL SYSTEMS, INC. (US) 2011-10-27 WO claimed
US-11971337-B2 Compositions and methods for simultaneous inactivation of alkaline phosphatase and peroxidase enzymes during automated multiplex tissue staining assays VENTANA MEDICAL SYSTEMS, INC. (US) 2024-04-30 US disclosed
US-20220026319-A1 COMPOSITIONS AND METHODS FOR SIMULTANEOUS INACTIVATION OF ALKALINE PHOSPHATASE AND PEROXIDASE ENZYMES DURING AUTOMATED MULTIPLEX TISSUE STAINING ASSAYS VENTANA MEDICAL SYSTEMS, INC. (US) 2022-01-27 US disclosed
US-11162877-B2 Compositions and methods for simultaneous inactivation of alkaline phosphatase and peroxidase enzymes during automated multiplex tissue staining assays VENTANA MEDICAL SYSTEMS, INC. (US) 2021-11-02 US disclosed
US-20180120202-A1 COMPOSITIONS AND METHODS FOR SIMULTANEOUS INACTIVATION OF ALKALINE PHOSPHATASE AND PEROXIDASE ENZYMES DURING AUTOMATED MULTIPLEX TISSUE STAINING ASSAYS VENTANA MEDICAL SYSTEMS, INC. 2018-05-03 US disclosed
EP-3295173-A1 COMPOSITIONS AND METHODS FOR SIMULTANEOUS INACTIVATION OF ALKALINE PHOSPHATASE AND PEROXIDASE ENZYMES DURING AUTOMATED MULTIPLEX TISSUE STAINING ASSAYS Ventana Medical Systems, Inc. (US) 2018-03-21 EP disclosed
WO-2016180747-A1 COMPOSITIONS AND METHODS FOR SIMULTANEOUS INACTIVATION OF ALKALINE PHOSPHATASE AND PEROXIDASE ENZYMES DURING AUTOMATED MULTIPLEX TISSUE STAINING ASSAYS VENTANA MEDICAL SYSTEMS, INC. (US) 2016-11-17 WO disclosed
EP-2606055-A1 SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF USE IN DETECTION ASSAYS AND KITS Ventana Medical Systems, Inc. (US) 2013-06-26 EP disclosed
US-20130115593-A1 SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF USE IN DETECTION ASSAYS AND KITS VENTANA MEDICAL SYSTEMS, INC. (US) 2013-05-09 US disclosed
EP-2561095-A1 TWO-COLOR CHROMOGENIC IN SITU HYBRIDIZATION Ventana Medical Systems, Inc. (US) 2013-02-27 EP disclosed
US-20130034853-A1 TWO-COLOR CHROMOGENIC IN SITU HYBRIDIZATION VENTANA MEDICAL SYSTEMS, INC. 2013-02-07 US disclosed
WO-2012024185-A1 SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF USE IN DETECTION ASSAYS AND KITS VENTANA MEDICAL SYSTEMS, INC. (US) 2012-02-23 WO disclosed
WO-2011133625-A1 TWO-COLOR CHROMOGENIC IN SITU HYBRIDIZATION VENTANA MEDICAL SYSTEMS, INC. (US) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130115593-A1 SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF USE IN DETECTION ASSAYS AND KITS ALPG, PYGL, DPYD EPHX1 722/4885HDAC1 3360/4885HDAC8 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.